drugset / Trial / NCT03742804

Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma

NCT03742804

Phase 2 Withdrawn Yale University
NaSingle-groupOpen-labelTreatment

Summary

The overall goal of this study is to evaluate the safety and immunogenicity of repeat-dose intratumoral G100 administration in patients with Cutaneous T Cell Lymphoma (CTCL) alone (Part 1) and following standard local radiation therapy or topical nitrogen mustard application (Part 2). Plaque, patch, or tumor lesions of CTCL may be injected. Disease will be assessed in all sites, including skin, nodes, and blood.

Timeline

Start
2019-06
Primary completion
2019-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucopyranosyl Lipid A Unknown Other